Common multiple sclerosis treatment linked to bowel disease risk
People with multiple sclerosis (MS) who are treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, although the absolute risk remains low. This is according to the first large population-based study in the field, led by researchers at Karolinska Institutet and published in JAMA Neurology.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Early uptake for oral semaglutide proves rapid relative to injectables
United Kingdom
-
Beyond the ACE score: A single number may miss the complexity of childhood trauma, study suggests
United Kingdom
-
ADHD medication unlikely to raise risk of self-harm, international study finds
United Kingdom
-
Adults with type 1 diabetes more likely to have depressive, anxiety symptoms
United Kingdom
-
Nurses are an important resource in Swedish bowel cancer screening
United Kingdom
-
Imaging study links several schizophrenia symptoms to a single brain signal
United Kingdom
-
Intermittent fasting plus exercise boosts fat loss and fitness in 12-week obesity trial
United Kingdom
-
Prevalence of binge eating 40.5% in U.S. high school students
United Kingdom